Drug Profile
Research programme: beta 3 adrenoreceptor agonists - sanofi-aventis
Alternative Names: SAR-150640Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Preterm labour
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Preterm-labour in France (Parenteral)
- 31 Aug 2007 Preclinical data added to the pharmacokinetics and Women's health pharmacodynamics sections
- 28 Feb 2007 Preclinical trials in Preterm labour in France (Parenteral)